C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B

22 Apr, 2021

C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B
Photo by Joshua Peacock on Unsplash

– C2i Genomics, a cancer detection company, raised $100m in Series B funding.
– The round was led by Casdin Capital and joined by new investors including New Enterprise Associates (NEA), and existing investors including Sequoia Capital, and others.
– The company plans to use the funding to expand its research and development efforts.

Genetics Health Care Health Diagnostics North America Therapeutics Wellness
Crunchbase icon

Content report

The following text will be sent to our editors: